Project Grant K08CA293271
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$911K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This $780,389 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) is supporting research to develop novel immunotherapies for acute myeloid leukemia (AML). The project aims to use state-of-the-art genetic engineering tools to generate "stealth" versions of key AML target genes, like FLT3, KIT, and IL3RA, that are resistant to CAR-T cell and monoclonal antibody therapies. This approach is intended to allow targeting of...
The National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $487,973 Project Grant to The Leland Stanford Junior University on January 1, 2025. This grant supports scientific research aimed at investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in the pathogenesis of acute myeloid leukemia (AML). The research will explore key questions related to the clonal evolution, kinetics, and cell non-autonomous effects of pHSCs,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $402,600.00 to the Sloan-Kettering Institute for Cancer Research to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP200 protein for the treatment of acute myeloid leukemia (AML). The key objectives are to: Test the efficacy and safety of the U5 snRNP200-targeted CAR T-cells, including engineered versions that secrete IL-18, in preclinical AML models....
This $1,144,895 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at The University of Texas Southwestern Medical Center to uncover therapeutic vulnerabilities in acute myeloid leukemia (AML). The primary objectives are to mechanistically define the essential co-regulators and direct targets of the transcription factor MECOM, which is critical for AML progenitor maintenance, and to identify indispensable downstream effectors...
This Project Grant award, valued at $2,775,137, was provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program. The primary awardee, The Trustees of Columbia University in the City of New York, will conduct research to investigate the role of aging-related factors, including transcriptional deregulation, inflammatory signals, and stromal niche changes, in the progression of acute myeloid leukemia (AML) from pre-AML states like age-related clonal...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Beckman Research Institute of the City of Hope to investigate the role, mechanism, and therapeutic potential of the RNA methyltransferase METTL1 in acute myeloid leukemia (AML). The $1,321,072 award, spanning June 2024 to May 2029, supports research across three specific aims: 1) further consolidating the importance of METTL1 function in AML using mouse models, 2)...
The National Cancer Institute (NCI) awarded a $342,102 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Johns Hopkins University to elucidate the role of the chromatin regulator HMGA1 in KMT2A-rearranged acute myeloid leukemia (AML). The project aims to define how HMGA1 drives leukemogenesis and chemoresistance in this aggressive form of AML, and determine how HMGA1 induces HOX genes and represses the CDKN1A tumor suppressor. The research will shed light on the...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) has awarded a $387,630 Project Grant to the University of Colorado-Denver to support research on targeting therapy-resistant leukemia initiating cells (LICs) in acute myeloid leukemia (AML). The goal is to characterize distinct LIC subtypes and their vulnerabilities in order to design more effective and durable therapies for AML patients, particularly those with therapy-resistant or TP53-mutant disease. The project will...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research to identify novel genes and mechanisms underlying therapy resistance and relapse in acute myeloid leukemia (AML). The 5-year, $458,698 grant awarded to the Regents of the University of Michigan aims to functionally validate candidate genes that confer growth advantages to leukemia cells and contribute to disease relapse despite initial remission. The research will...
The National Cancer Institute (NCI) awarded a $193,797 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Washington University in St. Louis, Missouri. The grant will fund a 3-year research project led by Dr. Jennifer Foltz to investigate the mechanisms of natural killer (NK) cell activation and immune-editing of acute myeloid leukemia (AML). The project aims to elucidate the transcriptional and epigenetic regulation of memory-like NK cells compared to...